|
|
Vaccine Detail
|
Sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine |
| Vaccine Information |
- Vaccine Name: Sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: oligosaccharide antigen sialyl Lewis (CA19-9) (NCT00470574; NCIT_C69000)
- Immunization Route: subcutaneous injection
- Description: The vaccine consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. (NCIT_C69000) The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells. (NCT00470574)
|
| Host Response |
|
|
| References |
NCIT_C69000: Sialyl Lewis-Keyhole Limpet Hemocyanin Conjugate Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000]
NCT00470574: Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer [https://clinicaltrials.gov/study/NCT00470574]
|
|
